Lithium Chloride: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Lithium Chloride

Other Diagnostic Agents

GB MHRA

Drug class: Other Diagnostic Agents
Availability: See label
Markets covered: 1
Products on record: 1

Overview

Lithium Chloride is an active pharmaceutical ingredient in the Other Diagnostic Agents group (V04CX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	May 15, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised May 15, 2026[1]

This medicinal product is for diagnostic use only. To be used only for the in-vivo measurement of cardiac output in conjunction with the LiDCO System.

How to take

Sources & citations

[1]MHRA (UK) · PL170480001 · revised May 15, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 15, 2026[1]

No undesirable effects related to lithium chloride are expected at the proposed posology.

GBOfficial regulatory label· Warnings and precautions· revised May 15, 2026[1]

4 Special warning and precautions for use This medicinal product must only be used in conjunction with the LiDCO System 1. Follow the dose recommendations. 5 mM. 2. All injections of lithium chloride should be recorded in the patient notes.
3. A minimum of 5 minutes should be left between sequential LiDCO System determinations of cardiac output. 4. Waste blood should not be returned to the patient. The waste blood may clot in the bag and/or pick up contaminant material/particles from contact with the Flow Through Cell assembly wick material.
5. g. vecuronium bromide, atracurium besylate and pancuronium bromide. These agents interfere with the performance of the lithium electrode and concurrent use must be avoided. 6. Lithium sensors are affected by other chemicals notably: detergents/surfactants and solvents.
Occasional problems have been noted with contaminants present in saline infusion products such as saline bags. 7. The use of the LiDCO System requires the bolus administration of lithium chloride and saline followed by arterial blood sampling.
Only medical staff appropriately qualified for the administration of intravenous fluids and peripheral arterial catheter use should use the system. Usual care should be taken to avoid: patient infection, catheter or line disconnection, arterial or venous blood loss and air embolism.
8. The concurrent use of: electrocautery, electrosurgery, defibrillation and X-ray machinery will cause transient interference with the LiDCO System Monitor trace. Determinations should not be performed during such periods. No such interference is known to occur with infrared irradiation, or equipment generating radiofrequency irradiation.
9 In cases of intracardiac shunt (such as myocardial infarction with interventricular septum rupture), the cardiac output measurement will be distorted when measured by the LiDCO System, as it would by the thermodilution method. An alternative method for cardiac output determination should be considered in such cases.
10. Lithium chloride should not be infused through a line used for the infusion of vasoactive or other potent drugs.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations